Penn’s Abramson Cancer Center Presents New Cancer Research at 2022 American Society of Hematology (ASH) Annual Meeting

Researchers from Penn’s Abramson Cancer Center presented the preliminary results of an ongoing Phase I clinical trial for a novel CAR T therapy to be used after cancer relapse at the 2022 American Society of Hematology (ASH) Annual Meeting.

The results showed successful re-treatment with CAR T cell therapy in patients whose cancers relapsed after previous CAR T therapy.

Additional research presented by researchers from the Abramson Cancer Center at the ASH Annual Meeting included a first-of-its-kind drug called modakafusp alfa, which has shown early potential in fighting against multiple myeloma, a form of bone marrow cancer.

Learn more about this cutting edge research here.

Skip to content